US 12,447,133 B2
Composition and device for preventing hypoglycemia and use thereof
Xiao Yu Wu, Toronto (CA); Jason Li, Toronto (CA); Amin Ghavami Nejad, Toronto (CA); Brian Lu, Toronto (CA); and Adria Giacca, Toronto (CA)
Assigned to THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, Toronto (CA)
Appl. No. 17/292,129
Filed by THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, Toronto (CA)
PCT Filed Nov. 8, 2019, PCT No. PCT/CA2019/051600
§ 371(c)(1), (2) Date May 7, 2021,
PCT Pub. No. WO2020/093173, PCT Pub. Date May 14, 2020.
Claims priority of provisional application 62/757,677, filed on Nov. 8, 2018.
Prior Publication US 2021/0393543 A1, Dec. 23, 2021
Int. Cl. A61K 9/70 (2006.01); A61K 9/00 (2006.01); A61K 38/26 (2006.01); A61P 3/10 (2006.01); C08J 3/075 (2006.01)
CPC A61K 9/7023 (2013.01) [A61K 9/0021 (2013.01); A61K 38/26 (2013.01); A61P 3/10 (2018.01); C08J 3/075 (2013.01)] 18 Claims
 
1. A composition for blocking or treating hypoglycemia comprising:
a microgel comprising crosslinked polymers containing glucose-responsive moieties; and
a blood glucose-raising therapeutic agent loaded on or within the microgel,
wherein the microgel further comprises a stabilizing component for the blood glucose-raising therapeutic agent,
wherein the stabilizing component is zwitterionic-based polymers, and the blood glucose-raising therapeutic agent is native glucagon.